Prospective Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel Infusion
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Tumors
Both
Tumors
Trial Information
Prospective Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel Infusion
In this study, there is no experimental treatment, or experimental care.
Inclusion Criteria:
- Chemotherapy with docetaxel or paclitaxel on an every 3-week schedule.
- Patient with bitherapy are eligible only if the taxane is the first infusion.
- All type of tumor.
- Age>18 years old.
- Signed written informed consent.
Exclusion Criteria:
- Patient under 18.
- Patient with bitherapy, if docetaxel or paclitaxel is not administered first.
- Patient deprived of liberty.
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label
Outcome Measure:
Evaluation of plasma alcohol
Outcome Description:
Measure of the plasma alcohol level before and after a taxane-based therapy (docetaxel or paclitaxel)
Outcome Time Frame:
One year
Safety Issue:
No
Principal Investigator
LE TOURNEAU Christophe, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Institut Curie
Authority:
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study ID:
IC 2011-03
NCT ID:
NCT01448759
Start Date:
October 2011
Completion Date:
October 2012
Related Keywords:
- Tumors
- Patients receiving docetaxel or paclitaxel. All tumors.
Name | Location |
|---|
